Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.
<h4>Background</h4>Intravenous thrombolysis using recombinant tissue plasminogen activator remains the mainstay treatment of acute ischemic stroke (AIS), although endovascular treatment is becoming standard of care in case of large vessel occlusions (LVO). To quantify the thrombus burden...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0254253 |
| _version_ | 1818694549272264704 |
|---|---|
| author | István Szegedi Rita Orbán-Kálmándi Attila Nagy Ferenc Sarkady Nikolett Vasas Máté Sik Levente István Lánczi Ervin Berényi László Oláh Alexandra Crișan László Csiba Zsuzsa Bagoly |
| author_facet | István Szegedi Rita Orbán-Kálmándi Attila Nagy Ferenc Sarkady Nikolett Vasas Máté Sik Levente István Lánczi Ervin Berényi László Oláh Alexandra Crișan László Csiba Zsuzsa Bagoly |
| author_sort | István Szegedi |
| collection | DOAJ |
| description | <h4>Background</h4>Intravenous thrombolysis using recombinant tissue plasminogen activator remains the mainstay treatment of acute ischemic stroke (AIS), although endovascular treatment is becoming standard of care in case of large vessel occlusions (LVO). To quantify the thrombus burden in LVO, a semiquantitative CT angiography (CTA) grading system, the clot burden score (CBS) can be used. Here we aimed to study the association between CBS and various hemostasis parameters, and to evaluate which parameters are major determinants of thrombolysis outcome.<h4>Methods</h4>In this single-centered prospective observational case-control study, 200 anterior circulation AIS patients receiving intravenous thrombolysis treatment without thrombectomy were enrolled: 100 AIS patients with LVO (CBS 0-9) and 100 age- and sex-matched AIS patients without LVO (CBS 10). Fibrinogen, α2-plasmin inhibitor, plasminogen, factor XIII and D-dimer were assessed from blood samples taken before and 24 h after thrombolysis, and FXIII-A Val34Leu was genotyped. CBS was calculated using admission CTA. Short-term outcomes were defined based on the change in NIHSS by day 7, long-term outcomes were assessed according to the modified Rankin scale at 3 months post-event.<h4>Results</h4>Poor outcomes were significantly more frequent in the CBS 0-9 group. Plasminogen activity on admission was significantly higher in the CBS 0-9 group. In a univariate analysis, significant protective effect of the Leu34 allele against developing larger clots (CBS 0-9) could be demonstrated (OR:0.519; 95%CI:0.298-0.922, p = 0.0227). Multivariate regression analysis revealed that CBS is an independent predictor of short- and long-term functional outcomes, while such effect of the studied hemostasis parameters could not be demonstrated.<h4>Conclusions</h4>CBS was found to be a significant independent predictor of thrombolysis outcomes. FXIII-A Leu34 carrier status was associated with smaller thrombus burden, which is consistent with the in vitro described whole blood clot mass reducing effects of the allele, but the polymorphism had no effect on thrombolysis outcomes. |
| first_indexed | 2024-12-17T13:31:21Z |
| format | Article |
| id | doaj.art-f9f2cb92308d4b51b52d72f1094f2e0f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T13:31:21Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f9f2cb92308d4b51b52d72f1094f2e0f2022-12-21T21:46:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025425310.1371/journal.pone.0254253Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.István SzegediRita Orbán-KálmándiAttila NagyFerenc SarkadyNikolett VasasMáté SikLevente István LáncziErvin BerényiLászló OláhAlexandra CrișanLászló CsibaZsuzsa Bagoly<h4>Background</h4>Intravenous thrombolysis using recombinant tissue plasminogen activator remains the mainstay treatment of acute ischemic stroke (AIS), although endovascular treatment is becoming standard of care in case of large vessel occlusions (LVO). To quantify the thrombus burden in LVO, a semiquantitative CT angiography (CTA) grading system, the clot burden score (CBS) can be used. Here we aimed to study the association between CBS and various hemostasis parameters, and to evaluate which parameters are major determinants of thrombolysis outcome.<h4>Methods</h4>In this single-centered prospective observational case-control study, 200 anterior circulation AIS patients receiving intravenous thrombolysis treatment without thrombectomy were enrolled: 100 AIS patients with LVO (CBS 0-9) and 100 age- and sex-matched AIS patients without LVO (CBS 10). Fibrinogen, α2-plasmin inhibitor, plasminogen, factor XIII and D-dimer were assessed from blood samples taken before and 24 h after thrombolysis, and FXIII-A Val34Leu was genotyped. CBS was calculated using admission CTA. Short-term outcomes were defined based on the change in NIHSS by day 7, long-term outcomes were assessed according to the modified Rankin scale at 3 months post-event.<h4>Results</h4>Poor outcomes were significantly more frequent in the CBS 0-9 group. Plasminogen activity on admission was significantly higher in the CBS 0-9 group. In a univariate analysis, significant protective effect of the Leu34 allele against developing larger clots (CBS 0-9) could be demonstrated (OR:0.519; 95%CI:0.298-0.922, p = 0.0227). Multivariate regression analysis revealed that CBS is an independent predictor of short- and long-term functional outcomes, while such effect of the studied hemostasis parameters could not be demonstrated.<h4>Conclusions</h4>CBS was found to be a significant independent predictor of thrombolysis outcomes. FXIII-A Leu34 carrier status was associated with smaller thrombus burden, which is consistent with the in vitro described whole blood clot mass reducing effects of the allele, but the polymorphism had no effect on thrombolysis outcomes.https://doi.org/10.1371/journal.pone.0254253 |
| spellingShingle | István Szegedi Rita Orbán-Kálmándi Attila Nagy Ferenc Sarkady Nikolett Vasas Máté Sik Levente István Lánczi Ervin Berényi László Oláh Alexandra Crișan László Csiba Zsuzsa Bagoly Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. PLoS ONE |
| title | Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. |
| title_full | Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. |
| title_fullStr | Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. |
| title_full_unstemmed | Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. |
| title_short | Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. |
| title_sort | decreased clot burden is associated with factor xiii val34leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis |
| url | https://doi.org/10.1371/journal.pone.0254253 |
| work_keys_str_mv | AT istvanszegedi decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT ritaorbankalmandi decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT attilanagy decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT ferencsarkady decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT nikolettvasas decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT matesik decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT leventeistvanlanczi decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT ervinberenyi decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT laszloolah decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT alexandracrisan decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT laszlocsiba decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis AT zsuzsabagoly decreasedclotburdenisassociatedwithfactorxiiival34leupolymorphismandbetterfunctionaloutcomesinacuteischemicstrokepatientstreatedwithintravenousthrombolysis |